Mechanistic Inhibition of CaN/FoxO1/FABP4 Signaling in Atherosclerosis: Insights from SERCA2 Dysfunction Models

Study Background and Research Question

Atherosclerosis remains a principal cause of cardiovascular morbidity and mortality worldwide. While the disease’s hallmark is the accumulation of lipid-rich plaques in arterial walls, the underlying cellular events—especially foam cell formation by macrophages—are complex and interconnected with both lipid metabolism and inflammatory signaling. Disruption of intracellular calcium homeostasis, particularly through altered function of sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2), has been implicated in vascular pathology, but the precise molecular mechanisms linking SERCA2 dysfunction to plaque progression were unclear. The reference study (Tong et al., 2025) specifically investigates whether SERCA2 dysfunction exacerbates atherosclerosis by disrupting fatty acid metabolism in macrophages, and if pharmacological targeting of downstream effectors could mitigate these effects.

Key Innovation from the Reference Study

The central innovation of this work lies in its elucidation of the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) signaling axis as a critical mediator of SERCA2 dysfunction-induced foam cell formation and atherosclerosis. Using a genetically engineered mouse model with a C674S knock-in mutation in SERCA2 (SKI mice), the authors demonstrate that loss of SERCA2 activity triggers CaN upregulation, FoxO1 nuclear translocation, and subsequent induction of FABP4. By dissecting this pathway, they reveal that pharmacological or genetic inhibition of FABP4 corrects aberrant fatty acid metabolism, thereby preventing foam cell formation and atherosclerotic lesion progression (Tong et al., 2025).

Methods and Experimental Design Insights

The investigators leveraged a multifaceted experimental design to probe mechanistic links between SERCA2 dysfunction and atherosclerosis. Heterozygous SERCA2 C674S knock-in (SKI) mice were generated to model pathological SERCA2 impairment. Serum metabolomics differentiated systemic metabolic alterations between SKI and wild-type controls. For cellular and molecular analyses, bone marrow-derived macrophages (BMDMs) from both genotypes were isolated and subjected to protein expression assays, lipid uptake and accumulation quantification, and histological analysis of aortic tissues. Importantly, the study utilized selective pharmacological inhibitors of FoxO1 and FABP4, alongside genetic partial deficiency models, to interrogate the roles of these pathway components in lipid homeostasis and foam cell formation. This integrative approach allowed the team to map the causative sequence from SERCA2 dysfunction to atherogenic outcomes.

Core Findings and Why They Matter

• SERCA2 C674S Mutation Drives CaN/FoxO1/FABP4 Pathway Activation: In SKI BMDMs, the dysfunctional SERCA2 led to increased calcineurin expression, which facilitated FoxO1 nuclear localization and upregulated FABP4 transcription. This resulted in enhanced fatty acid synthesis and foam cell formation, critical steps in atherosclerotic plaque development.
• Targeted Inhibition Mitigates Foam Cell Formation: Both genetic reduction and pharmacologic inhibition of FABP4—using agents such as BMS 309403—attenuated lipid accumulation and foam cell generation in vitro. In vivo, these strategies ameliorated atherosclerotic lesion progression in SKI mice.
• Correcting Aberrant Lipid Metabolism: Blocking the CaN/FoxO1/FABP4 axis normalized the expression of key lipid metabolism regulators, including ABCA1, ABCG1, and ACAT2, thereby restoring cholesterol efflux capacity and limiting toxic lipid accumulation in macrophages (Tong et al., 2025).

These findings are significant because they identify a tractable, druggable pathway linking a fundamental cell stressor (SERCA2 dysfunction) to a core pathogenic process (foam cell formation) in atherosclerosis. The demonstration that FABP4 inhibitors can intervene in this sequence provides a rational framework for developing targeted therapies and experimental models of cardiovascular disease.

Comparison with Existing Internal Articles

Several internal discussions have addressed the role of FABP4 inhibition in atherosclerosis and metabolic disease models. For example, "BMS 309403: Optimizing FABP4 Inhibitor Workflows in Atherosclerosis" highlights the precision with which BMS 309403 can dissect FABP4’s role in lipid metabolism and inflammation, supporting the reference study’s mechanistic findings. Additionally, "Strategic Inhibition of FABP4 with BMS 309403: Rationale and Roadmap" integrates protocol guidance and strategic perspectives for translational research, aligning with the reference paper’s evidence that pharmacological inhibition of FABP4 corrects foam cell formation and lesion development. These articles collectively reinforce that the CaN/FoxO1/FABP4 axis is a robust target for experimental and potential therapeutic intervention in cardiovascular and metabolic disease models.

Limitations and Transferability

Despite its strengths, the reference study has several limitations. The use of a single SERCA2 mutation model (C674S SKI mice) limits generalizability across other forms of SERCA2 dysfunction or cardiovascular disease etiologies. While the molecular and cellular findings in BMDMs are compelling, translation to human disease contexts requires validation in relevant human cell types and clinical samples. Furthermore, while the study robustly demonstrates the effect of FABP4 inhibition on atherosclerosis progression, long-term safety and specificity of pharmacologic inhibitors such as BMS 309403 in vivo remain to be fully characterized. The pathway’s interplay with other metabolic or inflammatory regulators was not exhaustively explored, which may affect the transferability of findings to broader disease settings.

Protocol Parameters

• Animal model: Heterozygous SERCA2 C674S knock-in (SKI) mice used to recapitulate SERCA2 dysfunction.
• Macrophage isolation: Bone marrow-derived macrophages (BMDMs) harvested from SKI and wild-type mice for in vitro assays.
• Pharmacological inhibition: FABP4 inhibitor applied at nanomolar to micromolar concentrations; literature suggests BMS 309403 is effective at 1–25 μM in cell-based assays (product information).
• Lesion analysis: Aortic root and entire aorta isolated for histological and quantitative assessment of atherosclerotic plaque burden.
• Metabolomic profiling: Serum collected for untargeted metabolomics to identify systemic lipid alterations.
• Protein and gene expression: Assessment of CaN, FoxO1, FABP4, and lipid metabolism regulators by immunoblotting and qPCR in BMDMs.

Research Support Resources

For researchers aiming to model or target the FABP4 pathway in studies of atherosclerosis, metabolic disease, or inflammation, selective inhibitors such as BMS 309403 (SKU B7794, APExBIO) provide a well-characterized tool for both in vitro and in vivo applications. BMS 309403 is a potent FABP4 inhibitor with high selectivity, enabling precise dissection of FABP4’s role within the calcineurin/FoxO1/FABP4 signaling axis. The compound is soluble in DMSO and ethanol, recommended for use at 1–25 μM in cell-based protocols, and can be stored at -20°C for long-term stability. Its use is supported by a growing body of literature in atherosclerosis and type 2 diabetes research, as detailed in the product information and internal workflow articles. Incorporating such reagents can facilitate reproducible, mechanism-driven research into lipid metabolism and inflammatory signaling in cardiovascular disease models.